(Novavax) Shares of Novavax rose more than 16% in premarket on Wednesday on news that the US Food and Drug Administration had approved its Covid-19 vaccine. Novavax said the FDA…
(Novavax) Shares of Novavax fell more than 25% in premarket on Tuesday after reporting adjusted earnings per share of $2.56 in the first quarter of 2022. The earnings missed expectations…
(Novavax) Shares of Novavax Inc. dropped by more than 7% on Tuesday after reporting a revenue of $222 million in the fourth quarter of 2021, compared to $280 million in…
(Novavax) Britain’s Medicines and Healthcare products Regulatory Agency has approved Novavax Inc.’s protein-based vaccine NVX-CoV2373. The vaccine would be the first protein-based for active inoculation against Covid-19 caused by SARS-CoV-2…
(Novavax) Shares of Novavax Inc. rose more than 5% in premarket on Thursday after preliminary findings showed that its Covid-19 vaccine produced strong immune responses against the Omicron. Novavax says…
(Reuters) Shares of Novavax rose more than 10% in pre-market on Monday on reports that it will begin deliveries of Covid-19 vaccines in the EU in the first quarter of…
(Novavax) Biotech firm Novavax announced $298 million in revenues in the second quarter ending June 30, up from 35.54 million reported in the comparable quarter of 2020. For the six…
(CNBC) Phase 3 clinical trials of Novavax vaccine trials on a sample of 29,960 participants have confirmed it is safe and 90.4% effective. Two-dose vaccine of Novavax was determined to…